Regentis GelrinC Reaches 50% U.S. FDA Trial Enrollment with 400% Yield Increase
RGNT•Regentis Biomaterials' GelrinC, a cell-free hydrogel implant with CE Mark in Europe, is over 50% enrolled in a pivotal U.S. FDA trial targeting 472,500 annual U.S. arthroscopic knee procedures. A patented solvent-free manufacturing process boosts GelrinC production yield by 400%, positioning the company for commercial scale-up as clinical milestones near.
1. GelrinC Platform and Market Opportunity
Regentis Biomaterials has developed GelrinC, a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single 10-minute procedure. The technology targets roughly 472,500 annual U.S. arthroscopic knee procedures by offering a ready-to-use regenerative solution, and has secured CE Mark approval in Europe.
2. U.S. FDA Trial Enrollment
The pivotal U.S. FDA trial for GelrinC is now over 50% enrolled, marking a key development toward potential market authorization in the United States. Continued patient recruitment and data collection are critical as the company advances toward pivotal clinical endpoints.
3. Patented Manufacturing Process
Regentis has patented a solvent-free manufacturing process that increases GelrinC production yield by 400%, reducing complexity and costs. This scale-up capability supports preparations for commercial launch pending regulatory approvals and aligns production capacity with anticipated demand.
